Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to (1) demonstrate the efficacy and safety (toxicity) of 25
mg/kg/day of Defibrotide in patients with severe veno-occlusive disease (sVOD) and (2)
evaluate serum and endothelial markers of veno-occlusive disease (VOD) through the analysis
of blood samples.